What You Need to Know Before Starting Your Practice: A Focus on Retinal Vein Occlusion

Supported by an educational grant from Regeneron Pharmaceuticals Inc.

This activity is jointly povided by

     and      

OVERVIEW

Treatment of patients with retinal vein occlusion (RVO) continues to evolve, with the emergence of new data and new diagnostic techniques. This leads to many questions for retina fellows contemplating the completion of their training and entering retina practice. This interactive, online, question-driven, video panel discussion between lead faculty and second-year retina fellows will provide participants with the opportunity to consider the efficacy and safety of available therapies, the use of emerging diagnostic techniques, and optimal treatment plans for patients.   

Target Audience

The goal of this activity is to provide retina fellows and practicing retina specialists with the most up-to-date clinical knowledge and strategies for the optimal treatment and management of patients with RVO. 

Additional information
Goal: 

The goal of this activity is to provide retina fellows and practicing retina specialists with the most up-to-date clinical knowledge and strategies for the optimal treatment and management of patients with RVO.

Accreditation Statement: 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and ASiM. Global is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement: 

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

After reviewing this online activity, participants may receive credit by completing the CME test, evaluation, and receiving a score of 70% or higher.

Term of Offering

This activity was released on March 31, 2017 and is valid for one year. Requests for credit must be made no later than March 31, 2018.

Copyright Information

All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information

There is no fee for this educational activity.

Confidentiality Disclaimer for CME Activity Participant: 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
Course opens: 
04/06/2017
Course expires: 
04/06/2018

Quan Dong Nguyen, MD, MSc (Co-Chair)
Omaha, Nebraska

Diana V. Do, MD (Co-Chair)
Omaha, Nebraska

Darius M. Moshfeghi, MD
Professor, Vitreoretinal Surgery 
Director, Ophthalmic Telemedicine
Byers Eye Institute
Stanford University of School of Medicine
Palo Alto, California
 
David S. Boyer, MD
Clinical Professor of Ophthalmology 
USC/Keck School of Medicine 
Partner Retina Vitreous Associates Medical Group
Los Angeles, California
 
Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania
 
Christina Y. Weng, MD, MBA
Assistant Professor-Vitreoretinal Diseases and Surgery 
Baylor College of Medicine
Houston, Texas
 
DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty/Presenters

Name of Faculty or Presenter

Reported Financial Relationship

David S. Boyer, MD

Served on a speakers’ bureau for Allergan Inc and Alcon; is a stockholder/shareholder in Allegro Ophthalmics LLC, Neurotech Pharmaceuticals Inc, OHR Pharmaceutical Inc, and Ophthotech Corporation; served as a consultant/independent contractor for Aerpio Therapeutics, Alcon, Alimera Sciences, Allegro Ophthalmics LLC, Allergan Inc, Bausch & Lomb Incorporated, Bayer, Boehringer Ingelheim GmbH, CoDa Therapeutics Inc, Foresite Biotherapeutics Inc, Genentech Inc, GenSite Biologics, Graybug Vision Inc, GlaxoSmithKline, Neurotech Pharmaceuticals Inc, Notal Vision Inc, Novartis, OHR Pharmaceutical Inc, Ophthotech Corporation, Optos, Regeneron Pharmaceuticals Inc, RetroSense Therapeutics, Regulus Therapeutics Inc, StemCells Inc, Sun Pharmaceutical Industries Inc, and ThromboGenics.

Darius M. Moshfeghi, MD

Received grant/research support from ThromboGenics; served as a consultant/independent contractor for Alcon, Genentech Inc, Iconic Therapeutics Inc, InSitu Therapeutics Inc, and Synergetics; and, is a stockholder/shareholder in: Grand Legend Technology.

Carl D. Regillo, MD, FACS

Received grant/research support from and served as a consultant/independent contractor for Alcon, Allergan Inc, Genentech Inc and Iconic Therapeutics Inc; received grant/research support from Iconic Therapeutics Inc and Regeneron Pharmaceuticals Inc; and served as a consultant/independent contractor for Bayer and Allegro Ophthalmics LLC.

Christina Y. Weng, MD, MBA

Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Planners/Managers

Name of Planner or Manager

Reported Financial Relationship

Quan Dong Nguyen, MD, MSc

Received grant/research support from and served as a consultant/independent contractor for Genentech Inc, Regeneron Pharmaceuticals Inc, and Santen Pharmaceutical Co Ltd; and received grant/research support from Novartis.

Diana V. Do, MD

Received grant/research support from and served as a consultant/independent contractor for Genentech Inc and Regeneron Pharmaceuticals Inc; received grant/research support from Novartis; and served as a consultant/independent contractor for Allergan Inc.

Christina M. Ohnsman, MD

Nothing to disclose

Andrea Funk

Nothing to disclose

Laura Gilsdorf

Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and ASiM do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™

Learning Objectives

After completing this activity, the participant should be better able to:

  • DESCRIBE various principles of retina practice management.
  • EVALUATE the latest clinical data for the treatment of RVO.
  • COMPARE the effect of dosing strategies on the efficacy and safety of current and emerging therapies for the management of RVO.

Accreditation Period

Course opens: 
04/06/2017
Course expires: 
04/06/2018
Please login or register to take this course.

Required Hardware/software

System Requirements

PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*

MAC
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Safari
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh.

*Required to view printable (PDF) version of the lesson.